PMID- 8941875
OWN - NLM
STAT- MEDLINE
DCOM- 19970303
LR  - 20221207
IS  - 1067-5582 (Print)
IS  - 1067-5582 (Linking)
VI  - 19
IP  - 5
DP  - 1996 Sep
TI  - Differences in frequency distribution of HLA-A2 subtypes between North American 
      and Italian white melanoma patients: relevance for epitope specific vaccination 
      protocols.
PG  - 357-63
AB  - Cytotoxic T lymphocytes (CTL) associated in vivo with tumor regression recognize 
      the product of nonmutated genes expressed by most melanoma cells as peptides 
      bound to human leukocyte antigen (HLA) molecules. Multiple HLA-A*0201 restricted 
      peptides derived from melanoma associated antigens (MAA) have been described, and 
      peptide-based vaccination protocols against melanoma are being developed 
      worldwide for the treatment of HLA-A2 melanoma patients based on the assumption 
      that most serologically typed HLA-A2+ individuals will be suitable for such 
      vaccinations. Serologic typing of HLA-A2, however, encompasses a family of at 
      least 17 related alleles recognized by molecular typing techniques and differing 
      at one or more functional residues of the HLA class I molecule. We have recently 
      shown that naturally occurring single-residue variants of HLA-A*0201 are 
      responsible for significant differences in CTL response to MAA-peptide 
      stimulation. Existing data for HLA-A*02 subtype frequencies among whites (who are 
      most affected by melanoma) derive from analyses of Northern European and North 
      American populations that are of similar heritage and predict an exceedingly rare 
      (< 5%) frequency of non-HLA-A*0201 alleles. Melanoma however, affects other white 
      populations in which the prevalence of HLA-A*02 alleles could be more variable. 
      This study was done to identify HLA-A*02 subtypes and their prevalence in two 
      ancestrally different white melanoma populations. HLA-A*02 subtype frequencies 
      were compared by polymerase chain reaction between serologically HLA-A2+ melanoma 
      patients referred for treatment to the Istituto Nazionale Tumori of Milan (n = 
      93), Italy or the National Cancer Institute, Bethesda, MD, U.S.A. (n = 100). This 
      analysis demonstrated differences in subtype specificity and distribution between 
      the two populations, with a significantly higher percentage of non HLA-A*0201 
      subtypes in the Italian population. Only 2% of serologically HLA-A2+ Northern 
      American white melanoma patients did not express HLA-A*0201. In contrast, 15% of 
      HLA-A2+ Italian patients were not HLA-A*0201 (p2 value = 0.001). As 
      allele-specific/peptide-based vaccination protocols are presently pursued at 
      several institutions, a proportion of patients might be inappropriately enrolled 
      basing their eligibility on serologically defined HLA-typing.
FAU - Player, M A
AU  - Player MA
AD  - National Cancer Institute, Department of Transfusion Medicine, National 
      Institutes of Health, Bethesda, MD 20892, USA.
FAU - Barracchini, K C
AU  - Barracchini KC
FAU - Simonis, T B
AU  - Simonis TB
FAU - Rivoltini, L
AU  - Rivoltini L
FAU - Arienti, F
AU  - Arienti F
FAU - Castelli, C
AU  - Castelli C
FAU - Mazzocchi, A
AU  - Mazzocchi A
FAU - Belli, F
AU  - Belli F
FAU - Parmiani, G
AU  - Parmiani G
FAU - Marincola, F M
AU  - Marincola FM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Immunother Emphasis Tumor Immunol
JT  - Journal of immunotherapy with emphasis on tumor immunology : official journal of 
      the Society for Biological Therapy
JID - 9418950
RN  - 0 (Cancer Vaccines)
RN  - 0 (Epitopes)
RN  - 0 (HLA-A2 Antigen)
SB  - IM
MH  - Amino Acid Sequence
MH  - Cancer Vaccines/*immunology
MH  - Epitopes/*immunology
MH  - Gene Frequency/*immunology
MH  - HLA-A2 Antigen/*immunology
MH  - Haplotypes/*immunology
MH  - Humans
MH  - Immunization Schedule
MH  - Italy/epidemiology
MH  - Melanoma/*immunology
MH  - North America/epidemiology
MH  - Skin Neoplasms/immunology
MH  - White People/*genetics
EDAT- 1996/09/01 00:00
MHDA- 1996/09/01 00:01
CRDT- 1996/09/01 00:00
PHST- 1996/09/01 00:00 [pubmed]
PHST- 1996/09/01 00:01 [medline]
PHST- 1996/09/01 00:00 [entrez]
AID - 10.1097/00002371-199609000-00005 [doi]
PST - ppublish
SO  - J Immunother Emphasis Tumor Immunol. 1996 Sep;19(5):357-63. doi: 
      10.1097/00002371-199609000-00005.